Definium Therapeutics News - June 24, 2026
Definium Therapeutics Announces ~$805M Public Offering of Common Stock
Definium Therapeutics, Inc. has entered into an underwriting agreement for a public offering of its common shares, expecting to raise approximately $758...
🟢 DFTX is trading 17% up today on Phase 3 trial success and $700M equity offering
DFTX is trading 17% up at $42.19 as investors react to positive Phase 3 results for its depression drug candidate and a significant capital raise. • The stock...
🟢 DFTX is trading 6.4% up today on Phase 3 Emerge data and analyst upgrades
DFTX is trading at $38.49 (+6.38%) in pre-market following a sharp rerating driven by positive Phase 3 Emerge data for DT120 ODT in major depressive...